used an E-Cadherin positive human lymphoma preclinical model (human Raji leukemia/lymphoma cells injected in NSG mice) to test therapeutic effects of CD103 expression on CD19-specific human CAR T cells. This evidence concerns the gene CD19 and lymphoma.